Developing and commercializing therapies for rare and challenging medical conditions.
| Title |
|---|
| Manager, Quality Systems Full Time · $120K-$137K · 8+ YOE Philadelphia, Pennsylvania, United States · Onsite |
| IT Systems Analyst Full Time · $105K-$147K Philadelphia, Pennsylvania, United States · Onsite |
| Manufacturing Specialist Full Time · $69K-$73K/yr · 1+ YOE Philadelphia, Pennsylvania, United States · Onsite |
| Manufacturing Specialist Full Time · $69K-$73K/yr · 1+ YOE Philadelphia, Pennsylvania, United States · Onsite |
| Regional Business Director, Mid Central Full Time · 10+ YOE Ohio or Alabama or Tennessee or Indiana or Kentucky or Michigan or Mississippi or West Virginia · Remote |
| Regional Business Director, Southwest Full Time · 10+ YOE United States · Remote |
| Sr Manager, Marketing Full Time · 10+ YOE Louisville, Kentucky, United States · Onsite |
| Quality Assurance Specialist Full Time · $83K-$108K/yr · 2+ YOE Philadelphia, Pennsylvania, United States · Onsite |
| Financial Analyst Full Time · 2+ YOE United States · Remote |
| Associate Director, Facilites Full Time · $150K-$175K · 12+ YOE Philadelphia, Pennsylvania, United States · Onsite |
| Facilities Engineer Full Time Philadelphia, Pennsylvania, United States · Onsite |
| Scientific Strategy Lead Full Time · $200K-$240K · 8+ YOE United States · Hybrid |
| Medical Science Advisor Full Time · $170K-$220K · 7+ YOE United States · Remote |
| Activities | Specialty pharmaceutical developmentCell therapy manufacturingOncology drug commercializationRare disease treatment licensingBiopharmaceutical product distribution |
| Headquarters | US |
| Industries | PharmaceuticalsBiotechnology |
| Name | US WorldMeds |
| Employees | 350 |
| Type | Private |
| Parent Company | US WorldMeds Partners |
| Subsidiaries | Solstice NeurosciencesHEMA BiologicsUSWM CT |
| Tagline | Developing and commercializing therapies for rare and challenging medical conditions. |
| Founded | 2,001 |
| Website | usworldmeds.com |
| Latest Funding Round | Debt Financing |
| Latest Funding Year | 2,025 |
| Latest Funding Amount | 235,000,000 |
| Latest Investors | Athyrium Capital Management |